BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vicadrostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vicadrostat\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07845630-369@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Vicadrostat: Phase 1 readout est. (NCT07845630)
DESCRIPTION:Vicadrostat\, phase 1.\nStudy: A Study in Healthy People to Com
 pare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets A
 re Taken up in the Body\nEstimated primary completion: 11 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07845630
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06531824-369@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06531824)
DESCRIPTION:Vicadrostat\, phase 3\, Chronic Kidney Disease.\nStudy: EASi-KI
 DNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combin
 ation With Empagliflozin)\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06531824
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304817-369@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Vicadrostat: Phase 2 readout est. (NCT07304817)
DESCRIPTION:Vicadrostat\, phase 2\, Heart Failure.\nStudy: Comparative Stud
 y on the Mode of Action of Vicadrostat and Spironolactone on Protein Profi
 les and Renal Hemodynamic Effects (COMPARE-VS)\nEstimated primary completi
 on: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vi
 cadrostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07304817
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424288-369@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20280522
DTEND;VALUE=DATE:20280523
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06424288)
DESCRIPTION:Vicadrostat\, phase 3\, Heart Failure.\nStudy: A Study to Test 
 Whether Vicadrostat in Combination With Empagliflozin Helps People With He
 art Failure\nEstimated primary completion: 22 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06424288
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935370-369@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06935370)
DESCRIPTION:Vicadrostat\, phase 3\, Heart Failure.\nStudy: A Study to Test 
 Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps Pe
 ople With Heart Failure and a Weak Pumping Function of the Left Side of th
 e Heart\nEstimated primary completion: 4 February 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06935370
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064473-369@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT07064473)
DESCRIPTION:Vicadrostat\, phase 3\, Type 2 Diabetes.\nStudy: EASi-PROTKT™
  - A Study to Test Vicadrostat (BI 690517) Taken Together With Empaglifloz
 in in People With Type 2 Diabetes\, High Blood Pressure\, and Cardiovascul
 ar Disease\nEstimated primary completion: 14 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07064473
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
